A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 May 2017 Planned End Date changed from 15 Mar 2019 to 8 Feb 2019.
- 16 May 2017 Planned primary completion date changed from 15 Mar 2019 to 23 Jul 2018.
- 16 May 2017 Status changed from not yet recruiting to recruiting.